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Abstract
It is now clearly established that coeliac disease is much more common than originally considered.
While in the past it was taught that coeliac disease was mainly a disease of children, it is clear now
that it may be diagnosed at any age. The clinical presentation of adolescents and adults is, however,
less typical. Recent evidence suggests that coeliac disease is a multi-organ disease. The diagnostic
techniques involving histology and serologic testing have been improved and the involvement of
environmental and genetic factors in the pathogenesis of this immune disorder has been clarified,
although the pathogenesis is not yet completely understood. Complications are now better identified,
and new treatment strategies are under consideration.
Introduction and context
“There is a kind of chronic indigestion which is met in persons
of all ages, yet is especially apt to affect children between one
and five years old. Signs of the disease are yielded by the faeces;
being loose, not formed, but not watery…” this is how
Samuel Gee described gluten-enteropathy in his paper
‘On the coeliac affection’ [1]. He also acknowledged the
findings of Aretaeus of Cappadocia who first wrote of
coeliac disease as far back as the second century, and
introduced the name ‘koiliakos’, a classic Greek term that
stands for suffering in the bowels . Over the last years it
has become clear however, that the disease may not be
limited to the bowel but affects also other systems.
As a result of the work of the Dutch paediatrician Dicke,
a gluten-free diet was recommended as the standard
treatment for the disease [2]. Standards for definition
and diagnosis were introduced in the 1970s [3], and
coeliac disease was defined by the European Society for
Paediatric Gastroenterology and Nutrition (ESPGAN) as
a ‘small intestinal mucosal lesion (villous atrophy)
associated with malabsorption and improvement with
dietary gluten withdrawal’.
Pathogenesis
Coeliac disease is a chronic inflammatory or immune
disease of the smallintestine triggered by dietary proteins
in wheat, rye and barley in genetically susceptible
individuals. Therefore, both environmental and genetic
factors play an important role in the pathogenesis. The
disease-activating proteins from the environment are
collectively termed ‘gluten’, but related prolamins can
also trigger the disease. The term ‘gluten’ refers to the
entire protein component of wheat, which comprises
gliadin and glutenin. Gliadin is the alcohol soluble
fraction that contains the bulk of the toxic components.
Undigested molecules of gliadin, such as a peptide from
an a-gliadin fraction, are resistant to degradation and
linger in the intestinal lumen before passing through the
epithelial barrier and interacting with antigen-presenting
cells, thereby promoting an inflammatory reaction.
The concordance for coeliac disease of 75–80% between
monozygotic twins stresses the importance of genetic
factors, but the genetics of coeliac disease is complex [4].
The main genetic risk factors are the human leukocyte
antigen (HLA)-DQ2/8 genotypes, which are thought to
account for 40% of the genetic predisposition [5].
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action involving both adaptive and innate immunity,
but the precise pathway or pathways are not yet
completely identified. Immunological studies of the
disease have shown that the immunodominant dietary
peptides’ (wheat gliadin) resistance to intestinal enzy-
matic breakdown, the modification of peptides by tissue
transglutaminase (tTG) and the presentation of peptides
to T cells by HLA-DQ molecules are all key steps leading
to the intestinal inflammatory response. The disease
associated HLA-DQ2 molecule has special features such
as the presence of several ‘pockets’ that favour binding of
negatively charged residues, such as those found in
gluten peptides. The enzyme tTG can modify gluten
peptides, so that they can bind to HLA-DQ molecules
and trigger the inflammatory T-cell response. The HLA-
DQ2 and HLA-DQ8 molecules predispose individuals to
coeliac disease by preferential presentation of gluten
peptides to CD4+ T-cells. The activated HLA-DQ2 or
HLA-DQ8 restricted T-cells produce mainly T helper (Th)
1 type cytokines, most notably interferon-gamma
(IFN-g), leading to the production of autoantibodies
such as anti-tTG. Gliadin peptides also activate an innate
immune response in the intestinal epithelium [6].
Epidemiology and clinical presentation
Four possible presentations of coeliac disease are
recognized: typical presentation with gastrointestinal
signs and symptoms (usually malabsorption, steator-
rhoea, and abdominal distention); atypical or extra-
intestinal presentation, where gastrointestinal symptoms
are minimal or absent but extraintestinal manifestations
prevail (such as anemia, osteoporosis, short stature, and
infertility); silent disease, where the small intestine is
damaged and serology positive but symptoms are not
present; and latent or potential disease, where indivi-
duals possess genetic characteristics but present with a
normal mucosa, may or may not be symptomatic, and
may show positive serology.
Diagnosis
The single most important step in diagnosing coeliac
disease is to first consider the possibility. There is no one
test that can completely exclude or diagnose coeliac
disease with 100% certainty because, just as there is a
continuum in the clinical spectrum, there is also a
continuum in histopathologic and laboratory results. All
diagnostic tests need to be performed while the patient is
on a gluten-containing diet.
The widespread availability of serologic tests has
permitted any physician to test for coeliac disease. The
detection of autoantibodies is often used as a first-line
test to identify individuals who might require a
duodenal biopsy. EMA (endomysial antibodies) and
tTG are currently the most recommended tests. The
sensitivity (+/- 93.9%) and specificity (96.5%) of the
second generation of immunoglobulin A (IgA) anti-tTG
assays are good [7], whereas there are reports of positive
tTG tests in the absence of coeliac disease [8] (which can
be seen in those with type 1 diabetes, chronic liver
disease, heart failure and psoriatic or rheumatoid
arthritis). It has been suggested that in some patients,
proteins other than tTG may act as antigens for anti-tTG
antibodies. It has also been suggested that in coeliac
disease patients with subtle lesions, the serology can
even be negative [9].
Small intestinal biopsy examination is the gold standard
for diagnosis. Biopsies of the descending duodenum,
rather than the more distal intestine, seem sufficient for
the diagnosis of coeliac disease, with jumbo forceps
having no marked advantage over standard size forceps
[10]. Due to the patchy nature of villous changes,
multiple biopsies are necessary, therefore it has been
suggested that at least four endoscopic biopsies must be
taken [11,12]. Ideally, the specimens should be orien-
tated properly in order to allow adequate assessment of
villous height and crypt depth. Based on the develop-
ment pattern of coeliac lesions and on the frequent
finding of cases with mild lesions, Marsh [13] proposed
a four stage classification: type 1 infiltrative lesion, a
normal mucosal architecture with an increased number
of intra-epithelial lymphocytes (IELs); type 2 hyperplas-
tic lesion, an increase in crypt depth without villous
flattening; type 3 destructive lesion, showing villous
atrophy and crypt hypertrophy; and type 4 hypoplastic
lesion, with villous atrophy, normal crypt height and IEL
count. Oberhuber et al. [14] and Corazza and Villanacci
[15] subsequently proposed modified schemes.
A major pitfall in diagnosis is the over-interpretation of
villous morphology, which can be attributed to
tangential sectioning. The recognition of the spectrum
of histological changes in coeliac disease as classified by
Marsh, or modifications of this classification, has
provided a major advantage in the diagnosis. The earliest
lesions still have a normal villous architecture but show
intra-epithelial lymphocytosis. In coeliac disease the IEL
count is more than 30 or 40 per 100 epithelial cells
(normally lower than 20) [16].
The HLA-DQ2 genotype is found in up to 90–95% of
patients with coeliac disease, while most of the remain-
ing patients have HLA-DQ8 [17]. In difficult cases,
determination of HLA-DQ may aid diagnosis, but it may
be not give a definite answer because these HLA alleles
are found in up to 40% of the general population.
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excludes a diagnosis of coeliac disease, apart from in
very rare cases.
Complications
Complications typically occur after many years of
disease, usually in adults. Coeliac disease carries an
increased risk for lymphoma, usually of T cell origin. The
associated high-grade lymphoma is known as entero-
pathy-associated T-cell lymphoma (EATL). There is also
an increased risk of adenocarcinoma of the small
intestine and possibly elsewhere in the gastrointestinal
tract. All-cause mortality among those with clinically
diagnosed coeliac disease is about twice that of a control
population [18].
Treatment
The cornerstone of treatment for coeliac disease is a life-
long gluten-free diet devoid of proteins from wheat,
barley, rye and related cereals. Even small quantities of
gluten may be harmful. Oats are tolerated by most
patients but can cause problems in some. There are
considerable differences between individual patients
with respect to clinical and mucosal responses to gluten
challenge.
Recent advances
Pathogenesis
Genetics
Recent genome-wide association studies point to a large
number of predisposing variants, each confering a risk
of variable size. The provisional list of predisposing loci
includes known CELIAC1 on chromosome 6 (HLA-DQ2
and HLA-DQ8), CELIAC2 on chromosome 5q31–33,
CELIAC3 on chromosome 2q33 (containing T-lympho-
cyte regulatory genes CD28, CTLA4 and ICOS), and
CELIAC4 (the myosin IXB gene, MYO9XB) on chromo-
some 19p13.1. It has been hypothesized that this latter
genetic variant might lead to an impaired intestinal
barrier [19,20]. Furthermore, associations with tight
junction genes PARD3 and MAG12 have been reported.
Genome-wide association studies also identified risk
variants in the 4q27 region harbouring IL2 and IL21
genes, and other regions harbouring genes controlling
immune responses, for example, leukocyte signalling in
response to IL-18 and IFN-g production [21,22].
From these studies it appears that the genetic predis-
position to coeliac disease depends on one gene with a
large effect on the adaptive immune response to gluten
peptides (HLA-DQ2/DQ8) and many other genes
influencing different aspects of innate and adaptive
immune reactions, intestinal permeability and predis-
position to autoimmunity [23,24]. It also appears that
coeliac disease and type 1 diabetes share HLA-DQ,
IL2-IL21, CCR3 and SH2B as risk factors [24,25].
Immunology
How Th1 cells are induced and maintained in the
mucosa has not been clear in the past. However, recent
data from duodenal mucosal biopsy studies suggest that
IL-21 may play a role in maintaining and expanding the
gluten-specific Th response [26]. Other data suggest that
IFN-a, produced by activated plasmacytoid dendritic
cells in the mucosa, may be the cytokine responsible for
polarizing the Th1 response. IFN-a can also upregulate
the expression of IL-21 mRNA in human T cells
stimulated via the T-cell receptor, so the interplay
between IL-21 and IFN-a may amplify the Th1 response.
IL-21 also interacts with IL-15 and they exert both
opposing and synergistic effects at the interface between
adaptive and innate immunity.
Some studies suggest that the innate immune compo-
nent of coeliac disease may result from an inherent defect
[abnormally increased expression of Toll-like receptor
(TLR) mRNA for TLRs 2 and 4 in the mucosa of coeliac
patients] [27]. This affects intestinal permeability and
may promote activation of antigen-presenting cells.
The release of cytokines such as IFN-a and IL-15 and the
expression of natural killer receptors at the surface of IELs
that recognize non-classical major histocompatibility
complex class I molecules (which are induced on the
surface of enterocytes by stress and inflammation), are
other mechanisms involved [28–30]. The interaction
leads to the activation of the lymphocytes to become
lymphokine-activated killing cells. IL-15 may promote
the expansion of IELs via natural killer receptors and
license their killing of enterocytes.
Epidemiology and clinical presentation
Recent findings estimate that about 1 in 133 people have
coeliac disease in Europe and the USA, with about
2,000,000 cases in the USA alone [31]. Most patients who
are diagnosed with coeliac disease present as adults but
family screening can identify ‘silent disease’ using a pro-
active case-finding strategy [32]. Studies have also shown
that coeliac disease may be more common in Africa,
South America, and Asia than previously believed. The
occurrence of the disease can show an epidemic
presentation such as that observed in Sweden in the
mid-1980s. To explain the different epidemiologies in
the Swedish epidemic, the model of an iceberg was
proposed; the whole iceberg represented people with a
genetic susceptibility, while the top represented sympto-
matic patients. Environmental exposures, including
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disease [33].
Typical presentations of diarrhoea and malabsorption
are more common in childhood, being observed in
almost 62% of the cases. Children also show a better
histologic recuperation. Presentation during adolescence
and adulthood is more atypical and can be oligosympto-
matic in adolescents, with typical presentation observed
in only 31% of adult patients [34]. Overall, the clinical
presentation has changed over the years because the
atypical forms are better recognized. Today, diarrhoea
occurs in less than 50% of patients at presentation
compared with nearly 100% of patients who presented
in the 1960s. Weight loss is now an uncommon feature.
It is now known that coeliac disease may frequently
co-exist with organ-specific or systemic autoimmune
diseases, such as type 1 diabetes mellitus, thyroiditis,
Sjogren’s syndrome, and connective tissue diseases.
Several hepatic disorders, including primary biliary
cirrhosis, and especially those of autoimmune etiology,
have also been described in patients with coeliac disease.
In patients with type 1 diabetes mellitus or thyroiditis,
screening may lead to a diagnosis of latent coeliac disease
in 5–10% of patients [35]. Coeliac patients most at risk
for autoimmune disease are those diagnosed early in life
and those that have a family history of autoimmunity. It
is not yet clear whether early diagnosis and treatment of
coeliac disease may lead to a decreased incidence or a
better clinical outcome of other autoimmune
disorders [36].
Diagnosis
There have been several recent advances in diagnosing
coeliac disease. For instance, it is now known that,
typically, a high increase in IELs can also be seen at the
top of the villi (Figure 1). The diagnostic yield will
increase when immunohistochemistry with antibodies
directed against T lymphocytes (CD3) is performed.
Intra-epithelial lymphocytosis is not, however, specific
for coeliac disease and may be seen in infective
enteropathies, Crohn’s disease, non-steroidal anti-
inflammatory drug usage, giardiasis and other condi-
tions. Furthermore, coeliac disease is not the only
possible cause of subtotal or total villous atrophy.
Other possibilities such as autoimmune enteropathy,
food intolerance, drug-use, radiation therapy and con-
ditions such as Zollinger-Ellison syndrome must also be
considered [37]. A recent study showed that, in difficult
cases, measuring anti-tTG antibody levels produced in
loco by the duodenal mucosa can help to establish the
diagnosis [9].
Endoscopic evaluation can aid diagnosis but is not
sufficient without biopsy [10]. Visible abnormalities that
have been described include mucosal pallor, scalloping
and a decrease in duodenal folds (Figure 2). The
introduction of new endoscopic techniques such as
confocal endomicroscopy may increase the diagnostic
yield, although this is unlikely to solve the differential
diagnostic issues.
Double-ballon enteroscopy improves the diagnosis of
refractory coeliac disease (RCD), which is associated with
complications such as ulcerative jejunitis and EATL,
and allows the delineation of the extent of these
complications.
Complications
A recent study found that the odds ratio for non-
Hodgkin lymphoma of any primary site associated with
Figure 2. Coeliac disease: endoscopy of the duodenum showing
loss of normal folds
Figure 1. Small intestinal villus with increased number of IELs:
Marsh classification type 1 (infiltrative lesion)
IEL, intra-epithelial lymphocyte.
Page 4 of 7
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:32 http://F1000.com/Reports/Medicine/content/1/32
..coeliac disease was found to be 3.1 times normal. For gut
lymphoma the odds ratio was 16.9 and for T-cell
lymphoma it was 19.2 [38]. In contrast, the increase in
relative risk for EATL in coeliac disease is not precisely
known because of its rarity; a recent study of the Dutch
population found that EATL had an estimated incidence
of 1 per 1,000,000 people per year. Deterioration of
coeliac disease is thought to be the most frequent
warning symptom of EATL [39]. Most EATLs are
localized in the proximal small intestine, and the
lymphoma may be multifocal, cause multiple ulcers,
strictures or tumour nodules. Bone marrow aspiration
and biopsy, as well as lumbar puncture, should be
performed for staging the lymphoma [40]. Some
evidence suggests that a gluten-free diet reduces lym-
phoma risk. In approximately 20% of the cases, the
associated coeliac disease is clinically occult.
Approximately 5% of patients have RCD, defined as
persistent symptoms and villous atrophy despite adher-
ence to a gluten-free diet for more than 12 months. RCD
may be subdivided into type I RCD, with normal IEL
phenotype, and type II RCD, with abnormal clonal IEL
type. Clonal refractory sprue (RCD II) is now considered
as a low-grade T-cell lymphoma. It is often the first step
of a transformation that may give rise to a high-grade
lymphoma, and is characteristically associated with
ulcerative jejunitis at endoscopy. At diagnosis, malnutri-
tion and lymphocytic gastritis are more common.
Non-clonal refractory sprue (RCD I) is not associated
with ulcerative jejunitis and more rarely complicated by
a lymphoma. Two cases were observed in a series of 14
patients with RCD I, whereas 16 overt lymphomas were
observed in a series of 43 patients with RCD II [41].
The distinction between RCD I and II is currently based
on immunophenotyping of T cells by immunohisto-
chemistry or flow-cytometric analysis of small bowel
biopsies, which screen for the presence of a significant
percentage of aberrant T cells. An abnormal phenotype
of IELs is a predictive factor, but not a necessary
condition, for the development of overt lymphoma
[41]. For the management of RCD II, high dose
chemotherapy followed by authologous stem cell
transplantation has been proposed. In contrast to
patients with a high percentage of aberrant T cells,
patients with RCD I seem to profit from treatment with
immunosuppressives.
Some evidence indicates that individuals with a sibling
affected with coeliac disease also have an excess risk for
non-Hodgkin lymphoma, which suggests a shared
susceptibility [42].
Treatment
Other approaches that would reduce the need for dieting
are being studied but are not yet ready for clinical
application. These include the use of gluten-degrading
enzymes to be ingested with meals, the development of
alternative gluten-free grains by genetic modification, the
use of substrates regulating intestinal permeability to
prevent gluten entry across the epithelium, and different
forms of immunotherapy [43]. Prolyl endopeptidases
from various bacterial and non-bacterial species appear
to be able to achieve gluten detoxification (glutenase
therapy). The use of antagonists of zonulin, a peptide
involved in the formation of tight junctions, has shown
promising preliminary results, and studies with peptides
that could block the binding of deamidated gliadin
peptides to DQ2 may have great potential [44].
Coeliac disease is now also well recognized as a disorder
that can affect other segments of the gastrointestinal tract
(lymphocytic gastritis and lymphocytic colitis can be part
of the condition) and it has even been classed as a
multisystem or multi-organ disorder that may affect
extra-intestinal organs, such as the skin, heart, nervous
system and liver [45,46].
Implications for clinical practice
The clinical presentation of coeliac disease is highly
variable, and the disease is now recognized as a multi-
system disorder. Recent advances show that the disease is
much more common than previously suspected, and
that diagnosis should be considered not only when there
are gastrointestinal symptoms, but also when extrain-
testinal manifestations such as anaemia or osteoporosis
are seen. Screening is indicated in relatives of patients
with established coeliac disease and in patients at risk,
such as those with type 1 diabetes and other auto-
immune diseases, as well as various neurological
syndromes including unexplained peripheral neuro-
pathy, epilepsy with occipital calcifications and ataxia.
Testing for coeliac disease is also needed in patients with
Down and Turner syndrome.
In most patients diagnosis is reached easily with serology
and duodenal biopsy. Immunohistochemistry for CD3
on small intestinal biopsy samples may also help
diagnosis. Roughly 10% of patients are difficult to
diagnose because of lack of concordance between
serology and histology, and in these cases testing for
HLA-DQ may be helpful.
Diet therapy remains the cornerstone of treatment.
A poor response to the diet is common and requires
extensive evaluation for dietary mistakes and to rule out
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treatment prevents complications.
Adenocarcinoma and lymphoma are major complica-
tions of coeliac disease, and RCD II is associated with a
much more severe clinical presentation and prognosis.
Recent advances suggest that immunophenotyping of T
cells from biopsies can help predict which patients will
develop overt lymphoma.
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